Sign In
Buy EMBC
$3.32
-0.170 (-4.87%)
At Close: Jun 03, 2026
EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth?
08:51am, Thursday, 20'th Nov 2025
Embecta's Q4 earnings loom as product momentum, global trends and recent strategic gains set the stage for potential top-line support.
embecta announces changes to Board of Directors
05:00pm, Monday, 17'th Nov 2025
PARSIPPANY, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based med
embecta Announces Major New Commitment to Direct Relief on World Diabetes Day
06:30am, Friday, 14'th Nov 2025
PARSIPPANY, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) -- On World Diabetes Day, embecta Corp. (“embecta”) (Nasdaq: EMBC), the largest manufacturer of insulin injection devices in the world, today annou
embecta to Report Fiscal Fourth Quarter and Full Year 2025 Financial Results
05:00pm, Tuesday, 11'th Nov 2025
PARSIPPANY, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based med
Best Value Stocks to Buy for October 6th
06:16am, Monday, 06'th Oct 2025
ELAN, DINO and EMBC made it to the Zacks Rank #1 (Strong Buy) value stocks list on October 6, 2025.
Best Value Stocks to Buy for September 9th
05:16am, Tuesday, 09'th Sep 2025
JXN, EMBC and KT made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 9, 2025.
Upgrading Embecta Due To Reorganization And Growth Initiatives
06:54am, Sunday, 31'st Aug 2025
Embecta's restructuring and discontinuation of the patch pump system have significantly improved profitability, enabling substantial cost savings and debt reduction. The company is refocusing on core
Embecta: Strategic Reprioritization Holds Promise And Valuations Are Favorable
08:22am, Thursday, 28'th Aug 2025
EMBC's strong Q3 results and improved profitability highlight management's effective cost controls, despite revenue growth being driven by one-off events. The new strategic direction focuses on streng
embecta to Participate in Investor Events
05:00pm, Tuesday, 26'th Aug 2025
PARSIPPANY, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical
Wall Street Analysts Predict a 25.69% Upside in Embecta Corp. (EMBC): Here's What You Should Know
10:55am, Tuesday, 12'th Aug 2025
The consensus price target hints at a 25.7% upside potential for Embecta Corp. (EMBC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings est
Embecta Corp. (EMBC) Q3 2025 Earnings Call Transcript
12:08pm, Friday, 08'th Aug 2025
Embecta Corp. (NASDAQ:EMBC ) Q3 2025 Earnings Conference Call August 8, 2025 8:00 AM ET Company Participants Devdatt Kurdikar - President, CEO & Director Jacob P. Elguicze - Senior VP & CFO Pravesh Kh
Embecta Corp. Reports Third Quarter Fiscal 2025 Financial Results
06:30am, Friday, 08'th Aug 2025
PARSIPPANY, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and ni
embecta Announces Quarterly Cash Dividend
06:00am, Friday, 08'th Aug 2025
PARSIPPANY, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstandi
embecta to Report Fiscal Third Quarter 2025 Financial Results
05:00pm, Thursday, 24'th Jul 2025
PARSIPPANY, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based med
embecta to Participate in Investor Events
05:00pm, Tuesday, 27'th May 2025
PARSIPPANY, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical
